Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
PDZ and LIM domain 1 pseudogene 3 (PDLIM1P3) is classified as a **pseudogene**, meaning it is a genomic sequence that closely resembles the functional gene PDZ and LIM domain 1 (PDLIM1) but is not believed to encode a functional protein product[1][4]. Pseudogenes typically arise by gene duplication or retrotransposition events and then accumulate disabling mutations, such as frameshifts or premature stop codons, rendering them generally non-functional at the protein-coding level[4]. PDLIM1P3 is not considered a therapeutic target, receptor, enzyme, transporter, or transcription factor. While some pseudogenes in general can exert regulatory effects at the RNA level (for example by acting as decoys for microRNAs or sources of regulatory non-coding RNAs), there is currently no evidence that PDLIM1P3 itself has such a functional role or disease association[2][4]. Its primary significance is as a genomic element related to, but distinct from, the protein-coding PDZ and LIM domain 1 gene.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on PDZ and LIM domain 1 pseudogene 3 (PDLIM1P3).